NEW YORK, Oct. 25 – Pfizer licensed Valentis’ GeneSwitch gene regulation technology, the companies announced on Wednesday.

The license is non-exclusive for research-use only.

Financial details of the agreement were not disclosed.

Burlingame, Calif.-based Valentis’ GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, according to the company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.